After a month of inactivity during the busiest year for IPOs since 2000, investors appear eager for IPOs as ReWalk Robotics flew up over 100% in Friday trading, the year's fifth IPO to do so. In addition to an annual August pause in the IPO market, large deals...read more
Affimed Therapeutics, a biotech developing immunotherapies for lymphomas, leukemia and other cancers, raised $56 million by offering 8 million shares at $7, below the range of $11 to $13. Affimed Therapeutics plans to list on the NASDAQ under the symbol AFMD....read more
After three weeks without an initial public offering, the IPO market's annual hiatus comes to a close with the two small health care companies expected in the upcoming week. IPO performance has improved recently, as the total return for IPOs year-to-date...read more
Affimed Therapeutics, an early-stage biotech developing immunotherapy antibodies to treat cancer, announced terms for its IPO on Tuesday. The Heidelberg, Germany-based company plans to raise $75 million by offering 6.25 million shares at a price range of $11 to...read more
US IPO Pricing Recap: ReWalk runs - year's 5th IPO to top 100% in first-day trading
After a month of inactivity during the busiest year for IPOs since 2000, investors appear eager for IPOs as ReWalk Robotics flew up over 100% in Friday trading, the year's fifth IPO to do so. In addition to an annual August pause in the IPO market, large deals...read more
Affimed Therapeutics prices IPO at $7, below the range
Affimed Therapeutics, a biotech developing immunotherapies for lymphomas, leukemia and other cancers, raised $56 million by offering 8 million shares at $7, below the range of $11 to $13. Affimed Therapeutics plans to list on the NASDAQ under the symbol AFMD....read more
Two health care IPOs planned for the week of September 8
After three weeks without an initial public offering, the IPO market's annual hiatus comes to a close with the two small health care companies expected in the upcoming week. IPO performance has improved recently, as the total return for IPOs year-to-date...read more
Immuno-oncology biotech Affimed Therapeutics sets terms for $75 million IPO
Affimed Therapeutics, an early-stage biotech developing immunotherapy antibodies to treat cancer, announced terms for its IPO on Tuesday. The Heidelberg, Germany-based company plans to raise $75 million by offering 6.25 million shares at a price range of $11 to...read more